Alyeska Investment Group’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $3.77M | Sell |
30,000
-176,368
| -85% | -$22.2M | 0.01% | 441 |
|
|
2025
Q1 | $22.8M | Sell |
206,368
-42,560
| -17% | -$4.71M | 0.09% | 228 |
|
|
2024
Q4 | $34M | Buy |
+248,928
| New | +$34M | 0.13% | 193 |
|
|
2024
Q3 | – | Sell |
-40,000
| Closed | -$5.51M | – | 630 |
|
|
2024
Q2 | $5.51M | Buy |
+40,000
| New | +$5.51M | 0.03% | 323 |
|
|
2019
Q1 | – | Sell |
-40,000
| Closed | -$2.86M | – | 382 |
|
|
2018
Q4 | $2.86M | Buy |
+40,000
| New | +$2.86M | 0.04% | 243 |
|
|
2017
Q3 | – | Sell |
-21,280
| Closed | -$979K | – | 480 |
|
|
2017
Q2 | $979K | Sell |
21,280
-11,612
| -35% | -$534K | 0.01% | 391 |
|
|
2017
Q1 | $1.42M | Sell |
32,892
-612,644
| -95% | -$26.5M | 0.01% | 403 |
|
|
2016
Q4 | $25M | Buy |
645,536
+204,301
| +46% | +$7.91M | 0.21% | 171 |
|
|
2016
Q3 | $22.3M | Sell |
441,235
-19,897
| -4% | -$1.01M | 0.21% | 163 |
|
|
2016
Q2 | $21M | Buy |
461,132
+119,439
| +35% | +$5.43M | 0.2% | 178 |
|
|
2016
Q1 | $13.5M | Buy |
341,693
+51,725
| +18% | +$2.05M | 0.12% | 215 |
|
|
2015
Q4 | $16.4M | Buy |
+289,968
| New | +$16.4M | 0.17% | 173 |
|